510 related articles for article (PubMed ID: 17613573)
41. Cortical somatosensory evoked potentials and spasticity assessment after botulinum toxin type A injection in children with cerebral palsy.
Boćkowski L; Okurowska-Zawada B; Sobaniec W; Kułak W; Sendrowski K
Adv Med Sci; 2007; 52 Suppl 1():171-5. PubMed ID: 18229658
[TBL] [Abstract][Full Text] [Related]
42. The combined effect of lower-limb multilevel botulinum toxin type a and comprehensive rehabilitation on mobility in children with cerebral palsy: a randomized clinical trial.
Scholtes VA; Dallmeijer AJ; Knol DL; Speth LA; Maathuis CG; Jongerius PH; Becher JG
Arch Phys Med Rehabil; 2006 Dec; 87(12):1551-8. PubMed ID: 17141633
[TBL] [Abstract][Full Text] [Related]
43. The role of botulinum toxin a in the management of lower limb spasticity in patients with cerebral palsy.
Dursun N; Dursun E; Alican D
Int J Clin Pract; 2002 Oct; 56(8):564-7. PubMed ID: 12425363
[TBL] [Abstract][Full Text] [Related]
44. [Treating writer's cramp: 14 years' experience with botulinum toxin].
Somma-Mauvais H; Soulayrol S; Duvocelle A; Azulay JP; Gastaut JL
Rev Neurol (Paris); 2010; 166(6-7):630-8. PubMed ID: 20189211
[TBL] [Abstract][Full Text] [Related]
45. [Treatment of spasticity with botulinum toxin].
Mémin B; Pollak P; Hommel M; Perret J
Rev Neurol (Paris); 1992; 148(3):212-4. PubMed ID: 1604136
[TBL] [Abstract][Full Text] [Related]
46. Efficacy and safety of 3- and 5-injection patterns (30 and 50 U) of botulinum toxin A (Dysport) for the treatment of wrinkles in the glabella and the central forehead region.
Rzany B; Ascher B; Fratila A; Monheit GD; Talarico S; Sterry W
Arch Dermatol; 2006 Mar; 142(3):320-6. PubMed ID: 16549707
[TBL] [Abstract][Full Text] [Related]
47. Pooled analysis of the safety of botulinum toxin type A in the treatment of poststroke spasticity.
Turkel CC; Bowen B; Liu J; Brin MF
Arch Phys Med Rehabil; 2006 Jun; 87(6):786-92. PubMed ID: 16731213
[TBL] [Abstract][Full Text] [Related]
48. An open label pilot investigation of the efficacy of Botulinum toxin type A [Dysport] injection in the rehabilitation of chronic anterior knee pain.
Singer BJ; Silbert PL; Dunne JW; Song S; Singer KP
Disabil Rehabil; 2006 Jun; 28(11):707-13. PubMed ID: 16809213
[TBL] [Abstract][Full Text] [Related]
49. Botulinum toxin A in the management of focal muscle overactivity in children with cerebral palsy.
Gibson N; Graham HK; Love S
Disabil Rehabil; 2007 Dec; 29(23):1813-22. PubMed ID: 18033606
[TBL] [Abstract][Full Text] [Related]
50. Botulinum toxin A for the treatment of delayed gastric emptying.
Friedenberg FK; Palit A; Parkman HP; Hanlon A; Nelson DB
Am J Gastroenterol; 2008 Feb; 103(2):416-23. PubMed ID: 18070232
[TBL] [Abstract][Full Text] [Related]
51. Therapeutic use of botulinum toxin type A in treating neck and upper-back pain of myofascial origin: a pilot study.
Lew HL; Lee EH; Castaneda A; Klima R; Date E
Arch Phys Med Rehabil; 2008 Jan; 89(1):75-80. PubMed ID: 18164334
[TBL] [Abstract][Full Text] [Related]
52. Mental techniques during manual stretching in spasticity--a pilot randomized controlled trial.
Bovend'Eerdt TJ; Dawes H; Sackley C; Izadi H; Wade DT
Clin Rehabil; 2009 Feb; 23(2):137-45. PubMed ID: 19164401
[TBL] [Abstract][Full Text] [Related]
53. Botulinum toxin A in the treatment of hemiplegic spastic foot drop--clinical and functional outcomes.
Chua KS; Kong KH; Lui YC
Singapore Med J; 2000 May; 41(5):209-13. PubMed ID: 11063169
[TBL] [Abstract][Full Text] [Related]
54. Evaluation of botulinum toxin A in treatment of tinnitus.
Stidham KR; Solomon PH; Roberson JB
Otolaryngol Head Neck Surg; 2005 Jun; 132(6):883-9. PubMed ID: 15944559
[TBL] [Abstract][Full Text] [Related]
55. Does low-dose botulinum toxin help the recovery of arm function when given early after stroke? A phase II randomized controlled pilot study to estimate effect size.
Cousins E; Ward A; Roffe C; Rimington L; Pandyan A
Clin Rehabil; 2010 Jun; 24(6):501-13. PubMed ID: 20483887
[TBL] [Abstract][Full Text] [Related]
56. Improvement in quality of life after botulinum toxin-A injections for idiopathic detrusor overactivity: results from a randomized double-blind placebo-controlled trial.
Sahai A; Dowson C; Khan MS; Dasgupta P
BJU Int; 2009 Jun; 103(11):1509-15. PubMed ID: 19389019
[TBL] [Abstract][Full Text] [Related]
57. [Botulinum toxin type A treatment of upper limb spasticity].
Wissel M; Wissel J
Wien Klin Wochenschr; 2001; 113 Suppl 4():16-9. PubMed ID: 15506047
[TBL] [Abstract][Full Text] [Related]
58. Evaluation of treatment protocols on minimal to moderate spasticity in multiple sclerosis.
Brar SP; Smith MB; Nelson LM; Franklin GM; Cobble ND
Arch Phys Med Rehabil; 1991 Mar; 72(3):186-9. PubMed ID: 1998451
[TBL] [Abstract][Full Text] [Related]
59. A randomized, placebo-controlled, crossover clinical trial of super blue-green algae in patients with essential blepharospasm or Meige syndrome.
Vitale S; Miller NR; Mejico LJ; Perry JD; Medura M; Freitag SK; Girkin C
Am J Ophthalmol; 2004 Jul; 138(1):18-32. PubMed ID: 15234278
[TBL] [Abstract][Full Text] [Related]
60. Botulinum neurotoxin type A injections reduce spasticity in mild to moderate hereditary spastic paraplegia--report of 19 cases.
Hecht MJ; Stolze H; Auf dem Brinke M; Giess R; Treig T; Winterholler M; Wissel J;
Mov Disord; 2008 Jan; 23(2):228-33. PubMed ID: 17999430
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
